KPV
KPV is typically discussed for inflammatory and gut support, but it remains a restricted compounding ingredient today.
Current status
Restricted
Inflammation and gut support, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Often considered a second-wave peptide that could benefit if FDA policy softens broadly.
Primary Use
Inflammation and gut support
Regulatory Timeline
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Sep 29, 2023
Current status signal recorded: Remains in the restricted class for routine compounding..
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Get notified...
Get notified when KPV status changes
State-specific notes
California
Generally unavailable from compliant in-state sources.